Metropolis Healthcare Limited (METROPOLIS) — Financial Results | 5 July 2026

· NSE 🔴 High Importance ✨ Positive
By StockFin Research Team AI-Assisted Analysis Source: BSE/NSE Filings

Metropolis Healthcare reported approximately 16% year-on-year revenue growth in Q1FY27 driven by patient volume expansion and favorable product mix, with TruHealth Wellness and Specialty segments leading growth and EBITDA margins improving year-on-year while remaining stable quarter-on-quarter.

📄 View Original Announcement (PDF)

About Metropolis Healthcare Limited (METROPOLIS)

Healthcare · Healthcare · Listed on NSE

Market Cap: ₹12,082.27 Cr P/E: 25.0 ROE: 13.5% ROCE: 19.8% Div Yield: 0.86%

View full METROPOLIS stock details →

📡 Get AI alerts when METROPOLIS files next

Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions

Track METROPOLIS — Free

📊 More METROPOLIS filings

See all METROPOLIS filings →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when METROPOLIS files new disclosures

Track METROPOLIS filings, board meetings, and corporate actions. Free email alerts at 5 PM.

Track METROPOLIS — Free

Free account · 2 AI queries/day